Therapix Biosciences Announces the Continued Development of THX-210 ( RESPECTRUM ) Cannabinoids Based Treatment for Autism Spectrum Disorder
p xmlns= http://www.w3.org/1999/xhtml span class= xn-location TEL AVIV, Israel, span class= xn-chron Dec. 2, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ( Therapix or the Company ) (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today the...